Valuation: KYORIN Pharmaceutical Co., Ltd.

Market Cap 66.35B 417M 357M 334M 306M 577M 39.94B 583M 3.96B 1.54B 20.05B 1.57B 1.53B P/E 2027 *
42.8x
P/E 2028 * 41x
Enterprise Value 66.35B 417M 357M 334M 306M 577M 39.94B 583M 3.96B 1.54B 20.05B 1.57B 1.53B EV / Sales 2027 *
0.53x
EV / Sales 2028 * 0.64x
Free-Float
60.02%
Yield 2027 *
2.16%
Yield 2028 * 2.16%
08-03 KYORIN Pharmaceutical Co., Ltd. Commences Promotion Activities For Allergic Conjunctivitis Treatment Alesion Eyelid Cream 0.5% CI
07-13 KYORIN Pharmaceutical Co., Ltd. and Santen Pharmaceutical Co., Ltd. Enter Joint Marketing Agreement for Allergic Conjunctivitis Treatment Alesion Cream 0.5% CI
05-12 KYORIN Pharmaceutical Co., Ltd. Provides Cash Dividend Guidance for the Second Quarter-End and Year-End of Fiscal Year Ending March 31, 2027 CI
05-12 Kyorin Pharmaceutical Co., Ltd. Announces Directorate and Executive Changes, Effective June 19, 2026 CI
05-12 KYORIN Pharmaceutical Co., Ltd. Announces Year-End Dividend for the Fiscal Year Ended March 31, 2026, Payable on June 4, 2026 CI
05-12 Kyorin Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the First Half and Full Fiscal Year Ending March 31, 2027 CI
04-27 Japanese Stocks Climb as Iran's Plan to Reopen Strait Boosts Sentiment MT
04-26 Kyorin Pharma Signs MOU to Transfer Generic Drug Business to Daito Group MT
04-24 Daito Pharmaceutical Co Ltd Signs MOU with Kyorin Pharmaceutical Co Ltd to Transfer Generic Drug Business to New Joint Venture CI
03-31 Kyorin Pharmaceutical Co Ltd - Kyorin enters into license agreement with Biodol for novel neuropathic pain treatment RE
03-25 Kyorin Pharmaceutical Co., Ltd. and Johnson & Johnson Enter Exclusive Distribution and Promotion Agreement for Sirturo CI
02-26 Kyorin Pharmaceutical Co., Ltd. Announces Executives Changes, Effective April 1, 2026 CI
02-04 Kyorin Wins Japan Approval for GeneSoC FluA/B Influenza Test Kit MT
1 day-0.26%
1 week+3.31%
Current month+1.14%
1 month-1.28%
3 months-14.70%
6 months-31.54%
Current year-24.85%
1 week 1,105
Extreme 1105
1,175
1 month 1,052
Extreme 1052
1,229
Current year 1,052
Extreme 1052
1,725
1 year 1,052
Extreme 1052
1,725
3 years 1,052
Extreme 1052
1,880
5 years 1,052
Extreme 1052
1,924
10 years 1,052
Extreme 1052
2,829
Manager TitleAgeSince
Chief Executive Officer 59 2023-03-31
Director of Finance/CFO 56 2023-03-31
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 59 2011-05-31
Director/Board Member 78 2013-05-31
Director/Board Member 66 2015-03-31
Change 5-day change 1-year change 3-year change Capi.($)
-0.26%+3.31%-26.20%-33.62% 418M
-0.71%+5.43%+79.39%+127.62% 1,119B
+1.04%+4.33%+53.43%+65.81% 651B
+0.18%+6.07%+27.94%+81.09% 468B
-1.38%+4.02%+42.52%+42.38% 374B
-0.52%+2.72%+25.21%+41.06% 302B
-1.06%+4.76%+2.00%+12.65% 259B
+0.35%+5.07%+52.75%+71.71% 238B
-0.53%+2.34%-18.53%-53.66% 208B
+0.19%+5.31%+28.16%+91.67% 181B
Average -0.27%+5.01%+26.67%+44.67% 380.03B
Weighted average by Cap. -0.22%+5.40%+45.92%+73.06%

Financials

2027 *2028 *
Net sales 125B 783M 671M 628M 574M 1.08B 75B 1.09B 7.43B 2.89B 37.66B 2.94B 2.88B 104B 655M 561M 525M 480M 906M 62.72B 916M 6.21B 2.42B 31.49B 2.46B 2.41B
Net income 1.55B 9.74M 8.35M 7.81M 7.14M 13.48M 933M 13.62M 92.43M 35.94M 468M 36.58M 35.79M 1.62B 10.18M 8.73M 8.16M 7.46M 14.09M 975M 14.24M 96.61M 37.57M 490M 38.24M 37.41M
Net Debt - -
Logo KYORIN Pharmaceutical Co., Ltd.
Kyorin Pharmaceutical Co Ltd, formerly Kyorin Holdings Inc, is a Japan-based company mainly engaged in the pharmaceuticals business. The Pharmaceuticals segment is mainly engaged in the manufacture, purchase, sales and testing of pharmaceutical products, the purchase of raw materials for pharmaceuticals, the evaluation of technologies, the inspection, analysis and negotiation of license affiliations, the operations related to clinical trials and information gathering such as searching for drug discovery seeds, as well as the drug candidate compound discovery research and compound evaluation business. The Company also conducts the diagnostic businesses and verifies and creates research targets that are directly linked to drug discovery.
Employees
1,982
Date Price Change Volume
26-08-24 JP¥1,155.00 -0.26% 229,800
26-08-21 JP¥1,158.00 -0.69% 215,000
26-08-20 JP¥1,166.00 +1.48% 309,000
26-08-19 JP¥1,149.00 +1.32% 334,800
26-08-18 JP¥1,134.00 +1.52% 401,400
Trader
-
Investor
Global
-
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
1
Last Close Price
1,155.00JPY
Average target price
1,100.00JPY
Spread / Average Target
-4.76%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4569 Stock